Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Achilles Therapeutics Plc (NQ: ACHL ) 0.7300 -0.0100 (-1.35%) Streaming Delayed Price Updated: 3:59 PM EDT, Aug 16, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Achilles Therapeutics Plc Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines May 22, 2024 From Achilles Therapeutics PLC Via GlobeNewswire Achilles Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights May 08, 2024 From Achilles Therapeutics PLC Via GlobeNewswire Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights April 04, 2024 From Achilles Therapeutics PLC Via GlobeNewswire Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning April 04, 2024 From Achilles Therapeutics PLC Via GlobeNewswire Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference February 05, 2024 From Achilles Therapeutics PLC Via GlobeNewswire Achilles Therapeutics Announces Publication of Nature Cancer ‘Comment’ on Strategy for Improved Neoantigen Immunogenicity Prediction December 18, 2023 Newly developed computational tools and large datasets with low bias will lead to robust neoantigen prediction and improved personalized cancer therapies From Achilles Therapeutics PLC Via GlobeNewswire Achilles Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights November 13, 2023 From Achilles Therapeutics PLC Via GlobeNewswire 10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis October 23, 2023 Via ACCESSWIRE Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation September 20, 2023 Via Investor Brand Network Exposures Product Safety Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation September 20, 2023 EQNX::TICKER_START (NASDAQ:GNPX),(OTCQX:RHHBY),(NASDAQ:JAZZ),(NASDAQ:ALXO),(NASDAQ:ACHL) EQNX::TICKER_END Via FinancialNewsMedia Exposures Product Safety Achilles Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights August 04, 2023 From Achilles Therapeutics PLC Via GlobeNewswire Achilles Therapeutics to Present at Upcoming Conferences June 12, 2023 From Achilles Therapeutics PLC Via GlobeNewswire Achilles Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights May 10, 2023 From Achilles Therapeutics PLC Via GlobeNewswire Achilles Therapeutics’ New Immunogenicity Prediction Application of its AI-Powered PELEUS™ Platform Uniquely Identifies the Most Potent T Cell Antigens May 10, 2023 - New AI module delivers a "Target-to-T cell” approach for revolutionizing the identification and prioritization of targets for personalized antigen approaches - From Achilles Therapeutics PLC Via GlobeNewswire Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement April 25, 2023 Achilles ADSs will continue to trade on the Nasdaq Global Select Market at this time, and the Company’s operations are not affected by the receipt of the Notice From Achilles Therapeutics PLC Via GlobeNewswire Achilles Therapeutics Announces Grant of US Patent Covering the Treatment of Patients with an Immunotherapy Targeting Neoantigens Based on Tumor HLA Status April 25, 2023 From Achilles Therapeutics PLC Via GlobeNewswire Achilles Therapeutics to Present at Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit April 17, 2023 From Achilles Therapeutics PLC Via GlobeNewswire Achilles Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Business Highlights March 07, 2023 From Achilles Therapeutics PLC Via GlobeNewswire Achilles Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference December 20, 2022 From Achilles Therapeutics PLC Via GlobeNewswire Achilles Therapeutics Presents Encouraging Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma at ESMO IO Congress 2022 December 06, 2022 From Achilles Therapeutics PLC Via GlobeNewswire Achilles Therapeutics to Present Early Proof of Concept of Safety and Clinical Activity of Clonal Neoantigen Reactive T Cells at the ESMO Immuno-Oncology Annual Congress 2022 November 30, 2022 From Achilles Therapeutics PLC Via GlobeNewswire Achilles Therapeutics Announces Grant of US Patent on Immunotherapies Targeting Clonal Neoantigens Identified Using Proprietary Method November 22, 2022 - US patent is for an immunotherapy targeting clonal neoantigens identified by the Achilles Clonality Engine (ACE), including vaccine, antibody, and autologous T cell therapy approaches - From Achilles Therapeutics PLC Via GlobeNewswire Achilles Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights November 08, 2022 From Achilles Therapeutics PLC Via GlobeNewswire Achilles Therapeutics Co-founder Professor Charles Swanton to Participate in Expert Roundtable Highlighting Pivotal Nature of Neoantigens as Targets in Cancer Cell Therapy October 06, 2022 From Achilles Therapeutics PLC Via GlobeNewswire Secarna Pharmaceuticals and Achilles Therapeutics Sign Research, Option and License Agreement to Develop Optimized T Cell Therapies November 10, 2021 - Secarna's LNAplusTM ASOs have the potential to optimize personalized T cell therapies being developed by Achilles - Secarna's industry-leading antisense oligonucleotide (ASO) platform LNAplusTM... From Secarna Pharmaceuticals GmbH & Co. KG Via AccessWire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.